title: Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
abstract: BACKGROUND
  Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four doses of FENDrix™ (HB-AS04), an adjuvanted HBV vaccine licensed in Europe for use in this population. This study evaluated persistence of immune response up to 36 months after primary vaccination.
  
  
  METHODS
  In this open, international, Phase III follow-up study, 151 pre-dialysis, peritoneal dialysis and hemodialysis patients ≥15 years of age received HB-AS02 at 0, 1, 6 months and 149 received HB-AS04 at 0, 1, 2, 6 months. Of these, 99 and 80 returned at Month 36, 76 and 62 of whom were eligible for inclusion in the Long-Term According-To-Protocol (LT-ATP) cohort for descriptive analysis of antibody persistence (mean age: 65.6 years).
  
  
  RESULTS
  At Month 36, 89.5% of subjects in the HB-AS02 group and 72.6% of those in the HB-AS04 group had anti-HBs antibody concentrations ≥10 mIU/ml. Anti-HBs antibody concentrations were ≥100 mIU/ml in 82.9% and 35.5% of subjects, respectively. Anti-HBs geometric mean antibody concentrations were higher in the HB-AS02 group over the 36 months of follow-up. An exploratory "time to boost" analysis confirmed that subjects who received HB-AS02 were 2.54 times more likely than those who received HB-AS04 to have anti-HBs antibody concentrations ≥10 mIU/ml at Month 36 (p=0.013 [95% CI: 1.22, 5.31]).
  
  
  CONCLUSIONS
  HB-AS02 candidate vaccine induces high and persistent anti-HBs antibody levels in pre-dialysis, peritoneal dialysis and hemodialysis patients, potentially reducing the need for booster doses in this population.
authors: Henogen SA, Gosselies, Belgium.
authors: Murielle
authors: M
authors: Surquin
authors: Christian
authors: C
authors: Tielemans
authors: Joëlle
authors: J
authors: Nortier
authors: Michel
authors: M
authors: Jadoul
authors: Patrick
authors: P
authors: Peeters
authors: Miroslav
authors: M
authors: Ryba
authors: Ludek
authors: L
authors: Roznovsky
authors: József
authors: J
authors: Domán
authors: Xavier
authors: X
authors: Barthelemy
authors: Priya Diana
authors: PD
authors: Crasta
authors: Marc
authors: M
authors: Messier
authors: Sophie
authors: S
authors: Houard
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood* / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D038622:Internationality; D008050:Lipid A / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention; D051437:Renal Insufficiency / Q000097:blood* / Q000276:immunology; D012503:Saponins / Q000276:immunology / Q000627:therapeutic use*; D035703:Therapies, Investigational; D014611:Vaccination / Q000379:methods
chemical_list: C501939:ASO2A adjuvant; D000276:Adjuvants, Immunologic; D004338:Drug Combinations; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D008050:Lipid A; D012503:Saponins